University of Haifa researchers find link between devastating disease and protein regulation in the brain.
University of Haifa researchers announced a link between Alzheimer’s disease and the activity level of a protein called eIF2alpha. The discovery — recently published in the journal Neurobiology of Aging – could offer a new treatment for this devastating disease. Israel is known for its research of Alzheimer’s disease and has patented technology that contributes to solving this worldwide problem. The latest study looks at ways to combat symptoms of the disease before they appear. In advanced stages of the disease, explains Prof. Kobi Rosenblum, head of University of Haifa’s Sagol Department of Neurobiology, small lumps (called plaques) are identified forming in the brain from a protein called amyloid. These plaques, he says, are typical of Alzheimer’s sufferers and undermine brain functioning. Much research has been directed at understanding these plaques and trying to eliminate them or restrict their formation and growth. The new study, conducted by research student Yifat Segev in the Laboratory for Research of Molecular and Cellular Mechanisms Underlying Learning and Memory, which is headed by Prof. Rosenblum, in cooperation with Prof. Danny Michaelson of Tel Aviv University, sought to identify factors that could be linked to Alzheimer’s even before the irreversible amyloid plaques are formed, and that are connected to the disease’s primary risk factor – age. A previous study co-authored by Canadian researchers and Prof. Rosenblum’s lab at the University of Haifa, revealed that cognitive abilities could be improved by altering the activity of the eIF2alpha protein, which regulates the creation of proteins in all cells, including nerve cells. That research gave Alzheimer’s researchers a glimmer of hope: Perhaps it would be possible to improve cognitive abilities or even prevent cognitive damage in Alzheimer’s patients at an early stage of the disease by intervening in the mechanisms that regulate protein generation in nerve cells. The current study compared mice that expressed the human Apoe4 gene – a gene known as a central risk factor for Alzheimer’s – with a group of mice with the parallel Apoe3 gene, which does not constitute a risk factor for the disease. Mice in the former group showed a change in the regulating mechanism for protein generation involving the eIF2alpha protein that damaged the cognitive abilities of those mice at a young age. This sort of mechanism change is characteristic of aging, and so also hinted at the tendency of these mice toward premature aging. According to Segev, this is the first time that a link has been found between the activity of eIF2alpha and the Apoe4 gene in relation to Alzheimer’s disease. She noted that modification treatments for the eIF2alpha mechanism are being widely researched and are developing quickly, and so the more we can understand about the connection between this mechanism and Alzheimer’s, the more we can find ways to identify and slow the progress of the disease.